ADMA Biologics (NASDAQ:ADMA) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of ADMA Biologics (NASDAQ:ADMA) in a report issued on Tuesday, Benzinga reports. HC Wainwright currently has a $7.50 price objective on the biotechnology company’s stock, up from their previous price objective of $6.00.

A number of other equities research analysts have also recently issued reports on the company. Mizuho boosted their price objective on ADMA Biologics from $9.00 to $10.00 and gave the stock a buy rating in a report on Friday, March 1st. Cantor Fitzgerald boosted their price target on ADMA Biologics from $6.50 to $8.00 and gave the company an overweight rating in a research note on Thursday, February 29th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of Buy and a consensus target price of $7.88.

ADMA Biologics Trading Down 2.1 %

Shares of NASDAQ:ADMA opened at $6.60 on Tuesday. ADMA Biologics has a 12-month low of $3.06 and a 12-month high of $6.76. The stock has a market cap of $1.51 billion, a PE ratio of -50.77 and a beta of 0.43. The business has a 50 day moving average of $5.62 and a 200-day moving average of $4.47. The company has a quick ratio of 1.69, a current ratio of 5.16 and a debt-to-equity ratio of 1.04.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. The company had revenue of $73.90 million during the quarter, compared to analysts’ expectations of $73.50 million. As a group, equities research analysts forecast that ADMA Biologics will post 0.3 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms sold 183,008 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $6.01, for a total transaction of $1,099,878.08. Following the completion of the transaction, the director now directly owns 2,577,387 shares in the company, valued at $15,490,095.87. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 639,895 shares of company stock worth $3,927,169 over the last three months. Corporate insiders own 6.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in shares of ADMA Biologics during the second quarter worth $34,000. Envestnet Asset Management Inc. acquired a new position in shares of ADMA Biologics during the first quarter worth $35,000. Price T Rowe Associates Inc. MD acquired a new position in shares of ADMA Biologics during the second quarter worth $35,000. Stephens Consulting LLC acquired a new position in shares of ADMA Biologics during the third quarter worth $36,000. Finally, Cerity Partners LLC acquired a new position in shares of ADMA Biologics during the second quarter worth $37,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.